Abeona Therapeutics Inc. (ABEO)
$4.52-7.76%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $258M
- Beta
- 1.30
- P/E (TTM)
- -3.98
- Short % float
- 46.11%
- Days to cover
- 11.6
- SI change
- +7.2%
- 1W
- -9.78%
- 1M
- -16.76%
- vs SPY 1W
- -9.64%
- vs SPY 1M
- -19.26%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 14
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-25.0%
REV YoY-
ROE-41.7%
EPS YoY-
ROA-35.0%
GROSS57
OP-328
NET-246
[VALUATION]
P/E TTM-3.98
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.01
P/FCF-
EV/EBITDA-3.10
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E15.52
ALTMAN Z-
CURR RATIO6.63
ND/EBITDA-
BETA1.30
Company news
FAQ
- What is LOPJLB’s current signal on ABEO?
- LOPJLB’s latest quantitative signal on Abeona Therapeutics Inc. (ABEO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ABEO in?
- Abeona Therapeutics Inc. (ABEO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Abeona Therapeutics Inc. (ABEO) do?
- Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also fe…